샘플 요청 목록

 카트 문의
시장보고서
상품코드
1793005

세계의 국소 진행성 췌장암 시장

Locally Advanced Pancreatic Cancer
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 375 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 국소 진행성 췌장암 시장은 2030년까지 17억 달러에 이를 전망

2024년에 9억 6,630만 달러로 추정되는 국소 진행성 췌장암 세계 시장은 2024-2030년 분석 기간에 CAGR 9.4%로 성장하여 2030년에는 17억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 화학요법은 CAGR 11.1%를 나타내고, 분석 기간 종료시에는 7억 5,010만 달러에 이를 것으로 예측됩니다. 면역치료 분야의 성장률은 분석 기간중 CAGR 10.5%로 추정됩니다.

미국 시장은 2억 6,330만 달러로 추정, 중국은 CAGR14.8%로 성장 예측

미국의 국소 진행성 췌장암 시장은 2024년에 2억 6,330만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년간 CAGR 14.8%로 2030년까지 3억 7,210만 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 4.7%와 9.0%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 6.3%를 나타낼 전망입니다.

세계의 국소 진행성 췌장암 시장 - 주요 동향과 촉진요인 정리

국소 진행성 췌장암이 암 분야에서 독자적으로 중요한 이슈인 이유는 무엇인가?

일반적으로 LAPC라고 불리는 국소 진행성 췌장암은 췌장 악성 종양의 복잡하고 침습적인 병기를 나타내며, 주변 구조물로의 전이는 관찰되나 원격 장기로의 전이는 아직 관찰되지 않습니다. 이 분류에는 중요한 혈관을 침범한 종양도 포함되며, 진단 시 기존 수술 방법으로는 수술이 불가능한 경우도 포함됩니다. LAPC의 문제는 무증상 진행과 비특이적 증상으로 인해 발견이 늦어지고 치료 기간이 제한되는 경우가 많다는 점입니다. 전이성이 아님에도 불구하고 LAPC는 전신 전이 위험이 높고, 전반적인 예후가 좋지 않으며, 5년 생존율이 매우 낮습니다. 종양은 종종 기존 치료에 저항하고 빠르게 진행하기 때문에 그 치료는 국소 병변 조절과 전신 치료의 미묘한 균형이 필요합니다. 췌장암의 생물학적 특성은 매우 복잡하고, 간질 환경이 치밀하고, 면역세포의 침윤이 제한적이며, 화학요법이나 방사선 요법에 본질적으로 저항성이 있는 것이 특징입니다. 그 결과, LAPC는 많은 경우 화학요법, 방사선요법, 그리고 일부의 경우 종양의 병기 축소 후 수술적 재평가를 결합한 다약제 병용요법 전략이 필요한 과도기적 치료로 간주됩니다. 환자의 정신적, 육체적 부담이 크고, 임상적 개입과 병행하여 지지요법이 필요합니다. 췌장암에서 LAPC의 역할을 이해하는 것은 예후를 개선하는 데 매우 중요합니다. 왜냐하면 LAPC는 적극적이고 협력적인 치료가 효과적으로 적용된다면 생존과 삶의 질에 영향을 미칠 수 있는 중요한 분기점이기 때문입니다.

국소 진행성 췌장암의 치료 접근법은 어떻게 진화하고 있는가?

국소 진행성 췌장암의 치료 전략은 전신요법, 표적치료, 영상진단의 발전 등으로 최근 크게 발전하고 있습니다. 역사적으로 치료는 주로 질병의 진행을 늦추기 위한 완화적 화학요법이 주를 이루었으나, FOLFIRINOX와 젬시타빈-냅-파클리탁셀과 같은 다제 병용 화학요법이 종양의 축소와 생존율 개선에 대한 유망한 결과를 보여줌에 따라 이러한 접근법이 변화하고 있습니다. 이러한 요법은 현재 종양 반응을 평가하고 절제 가능한 상태로의 전환 가능성을 평가하기 위한 1차 치료법으로 일반적으로 사용되고 있습니다. 좋은 반응을 보인 환자에게는 수술적 절제술이라는 선택이 가능해져 이전에는 달성할 수 없었던 근치적 절제술의 가능성이 생겼습니다. 방사선 치료, 특히 정위적 방사선 치료(SBRT)나 세기변조 방사선 치료(IMRT)와 같은 첨단 치료법은 화학요법과의 병용 또는 전신 치료 후의 지반 요법으로 국소 종양 조절을 위해 점점 더 많이 사용되고 있습니다. 임상시험에서는 면역요법, 항혈관신생제, 종양조직의 분자 프로파일링에 기반한 맞춤의료 등의 새로운 조합도 검토되고 있습니다. BRCA 돌연변이 및 불일치 복구 결손과 같은 유전자 검사 및 바이오마커의 통합은 특정 환자 집단에서 PARP 억제제를 포함한 표적 치료제의 사용을 유도하고 있습니다. LAPC를 관리하기 위해서는 종양내과 전문의, 외과 전문의, 방사선과 전문의, 완화치료 전문의, 영양사 등이 참여하는 다학제 치료팀이 필수적이며, 종합적인 치료 계획을 제공합니다. 이러한 진화된 접근법은 치료의 전망을 재구성하고, 역사적으로 어려운 진단을 받은 환자들에게 새로운 희망을 가져다주고 있습니다.

LAPC 관리에 영향을 미치는 환자 중심 트렌드와 진단 트렌드는 어떤 것들이 있을까?

국소 진행성 췌장암의 치료는 환자 중심의 치료 모델과 보다 정확한 치료 계획을 가능하게 하는 진단 도구의 발전으로 점점 더 많은 영향을 받고 있습니다. 큰 흐름 중 하나는 조영 CT, MRI, PET 등의 고해상도 영상진단 기술을 사용하여 종양과 주변 혈관계와의 연관성을 평가하고 절제 가능성을 판단하는 것입니다. 이러한 영상 진단은 치료 방침을 결정하는 데 도움이 되며, 전신 치료 후 수술로 전환할 수 있는 잠재적 후보를 식별하는 데 도움이 됩니다. 또 다른 중요한 발전은 초음파 내시경(EUS)과 세침흡입법의 병용입니다. EUS는 병리조직학적 진단과 유전자 분석을 위한 조직 채취를 가능하게 하여 개인 맞춤형 치료의 길을 열어줍니다. 환자 보고에 의한 결과 또한 치료 효과 평가에 있어 주목받고 있으며, QOL, 증상 조절, 기능적 상태가 기존의 생존 지표와 함께 고려되고 있습니다. 체중 감소, 피로, 복부 불편감은 LAPC 환자에서 흔히 나타나는 쇠약 증상으로, 영양 지원과 통증 관리는 치료의 필수적인 요소입니다. 원격의료는 특히 종양 전문 의료에 대한 접근성이 제한된 지역에서 빈번한 추적 관찰과 다학제적 진료를 용이하게 하고 있습니다. 예후가 제한적인 경우가 많은 진단에 따른 정신적 부담을 고려하여 심리적 지원과 상담이 필수적으로 요구되고 있습니다. 의사결정 공유 프레임워크는 환자가 치료 선택에 적극적으로 참여할 수 있는 권한을 부여하고, 개입이 개인의 가치와 목표에 부합하는 방향으로 이루어질 수 있도록 합니다. 이러한 환자 중심 트렌드와 진단의 변화는 LAPC를 관리하기 위한 보다 맞춤화되고 총체적인 접근을 통해 치료의 질을 향상시키는 데 기여하고 있습니다.

국소 진행성 췌장암에 대한 연구와 임상적 초점이 확대되는 주요 원동력은 무엇인가?

국소 진행성 췌장암에 대한 연구와 임상적 관심의 확대는 발병률 증가, 미충족 의료 수요, 기술 혁신, 그리고 이 질환에 특화된 치료 영역에 대한 인식 증가와 맞물려 이루어졌습니다. 인구의 고령화와 비만, 당뇨병 등 생활습관의 영향으로 췌장암의 발병률은 전 세계적으로 지속적으로 증가하고 있으며, LAPC의 부담은 더욱 두드러지고 있습니다. 이 단계의 높은 사망률로 인해 생존율과 삶의 질을 모두 개선할 수 있는 보다 효과적인 치료법을 찾기 위한 노력이 강화되고 있습니다. 유전체학 및 바이오마커 연구의 발전으로 종양 생물학에 대한 보다 세밀한 이해가 가능해졌고, 연구자들은 LAPC에 특이적인 분자 아형과 치료 표적을 식별할 수 있게 되었습니다. 제약회사와 학계는 종양의 자연 저항성을 극복할 수 있는 새로운 약물 조합, 면역관문억제제, 방사선 감작제를 탐색하는 임상시험에 대한 투자를 늘리고 있습니다. 전 세계 암 단체와 환자 옹호 단체의 자금 지원은 조기 진단과 치료 혁신을 위한 인식 개선 캠페인과 연구비 지원을 지원하고 있습니다. 적응형 임상시험 설계의 출현으로 치료법을 실시간으로 보다 효율적으로 평가할 수 있게 되면서 새로운 표준 치료법으로 가는 길이 가속화되고 있습니다. 인공지능과 머신러닝 도구는 영상 진단과 치료 계획에 적용되어 환자 결과를 최적화할 수 있는 데이터 기반 통찰력을 제공합니다. 협력 네트워크가 확대되고 치료 프로토콜이 더욱 정교해짐에 따라 LAPC에 대한 전 세계의 관심은 임상 경로를 개선하고 향후 몇 년 동안 획기적인 진전을 이룰 수 있는 모멘텀을 창출하고 있습니다.

부문

치료법(화학요법, 면역치료, 표적치료, 방사선 요법, 수술);투여 경로(경구 투여, 주사제 투여, 기타 투여 경로);최종 사용(병원 및 진료소 최종 사용, 외래수술센터(ASC) 최종 사용, 기타 최종 사용)

조사 대상 기업 예

  • AB Science
  • Actuate Therapeutics Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Candel Therapeutics, Inc.
  • Clovis Oncology, Inc.
  • Eli Lilly and Company
  • EXACT Therapeutics
  • F. Hoffmann-La Roche Ltd.
  • FibroGen, Inc.
  • Fresenius Kabi AG
  • GlaxoSmithKline plc(GSK)
  • Ipsen Pharma
  • Merck & Co., Inc.
  • Novartis AG
  • Novocure Limited
  • Oncolytics Biotech Inc.
  • Pfizer Inc.
  • RenovoRx
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Verastem, Inc.

AI 통합

당사는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 큐레이트된 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH

Global Locally Advanced Pancreatic Cancer Market to Reach US$1.7 Billion by 2030

The global market for Locally Advanced Pancreatic Cancer estimated at US$966.3 Million in the year 2024, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 9.4% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 11.1% CAGR and reach US$750.1 Million by the end of the analysis period. Growth in the Immunotherapy segment is estimated at 10.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$263.3 Million While China is Forecast to Grow at 14.8% CAGR

The Locally Advanced Pancreatic Cancer market in the U.S. is estimated at US$263.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$372.1 Million by the year 2030 trailing a CAGR of 14.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.7% and 9.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.3% CAGR.

Global Locally Advanced Pancreatic Cancer Market - Key Trends & Drivers Summarized

Why Is Locally Advanced Pancreatic Cancer a Unique and Critical Challenge in Oncology?

Locally advanced pancreatic cancer, commonly referred to as LAPC, represents a complex and aggressive stage of pancreatic malignancy that has spread to nearby structures but has not yet metastasized to distant organs. This classification includes tumors that involve critical blood vessels, rendering them inoperable by traditional surgical methods at diagnosis. The challenge with LAPC lies in its silent progression and non-specific symptoms, which often leads to late detection and limited treatment windows. Despite not being metastatic, LAPC carries a high risk of systemic spread and poor overall prognosis, with five-year survival rates remaining dismally low. Its management requires a delicate balance of local disease control and systemic therapy, as the tumor often resists conventional treatment and progresses rapidly. The biology of pancreatic cancer itself is notoriously complex, marked by a dense stromal environment, limited immune cell infiltration, and intrinsic resistance to chemotherapy and radiotherapy. As a result, LAPC is often considered a transitional phase that requires multimodal therapeutic strategies combining chemotherapy, radiation, and in select cases, surgical re-evaluation after tumor downstaging. The emotional and physical toll on patients is significant, necessitating supportive care services alongside clinical intervention. Understanding LAPC’s role in the pancreatic cancer spectrum is critical to improving outcomes, as it represents a key juncture where aggressive, coordinated care may still influence survival and quality of life if applied effectively.

How Are Therapeutic Approaches Evolving for the Management of Locally Advanced Pancreatic Cancer?

Therapeutic strategies for locally advanced pancreatic cancer have evolved significantly in recent years, driven by advances in systemic therapy, targeted treatments, and improved diagnostic imaging. Historically, treatment focused primarily on palliative chemotherapy to slow disease progression, but this approach has shifted as multi-agent chemotherapy regimens such as FOLFIRINOX and gemcitabine-nab-paclitaxel have shown promise in shrinking tumors and improving survival. These regimens are now commonly used as first-line treatment to assess tumor response and evaluate potential conversion to resectable status. For patients who demonstrate a good response, the option of surgical exploration may become viable, offering a chance for curative resection that was previously unattainable. Radiation therapy, particularly with advanced modalities like stereotactic body radiotherapy (SBRT) and intensity-modulated radiation therapy (IMRT), is increasingly being used for local tumor control, either in combination with chemotherapy or as consolidation therapy after systemic treatment. Clinical trials are also exploring novel combinations of immunotherapy, anti-angiogenic agents, and personalized medicine based on molecular profiling of tumor tissue. The integration of genetic testing and biomarkers such as BRCA mutations and mismatch repair deficiency is guiding the use of targeted therapies, including PARP inhibitors, in select patient populations. Multidisciplinary care teams are essential in managing LAPC, involving oncologists, surgeons, radiologists, palliative care specialists, and nutritionists to provide comprehensive treatment plans. These evolving approaches are reshaping the treatment landscape and offering new hope for patients with a historically grim diagnosis.

What Patient-Centered and Diagnostic Trends Are Influencing the Management of LAPC?

The management of locally advanced pancreatic cancer is increasingly influenced by patient-centered care models and advances in diagnostic tools that enable more precise treatment planning. One major trend is the use of high-resolution imaging technologies such as contrast-enhanced computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans to assess tumor involvement with surrounding vasculature and determine resectability. These imaging modalities help guide treatment decisions and identify candidates for potential surgical conversion after systemic therapy. Another critical development is the use of endoscopic ultrasound (EUS) with fine-needle aspiration, which enables tissue sampling for histopathological diagnosis and genetic analysis, paving the way for individualized therapy. Patient-reported outcomes are also gaining prominence in evaluating treatment efficacy, as quality of life, symptom control, and functional status are considered alongside traditional survival metrics. Nutritional support and pain management are essential components of care, as weight loss, fatigue, and abdominal discomfort are common and debilitating symptoms in LAPC patients. Telemedicine is facilitating frequent follow-up and multidisciplinary consultations, especially in areas where access to specialty oncology care is limited. Psychological support and counseling are becoming integral, acknowledging the emotional strain associated with a diagnosis that often carries a limited prognosis. Shared decision-making frameworks are empowering patients to engage actively in their treatment choices, ensuring that interventions align with personal values and goals. These patient-centered and diagnostic trends are improving the delivery of care and contributing to more tailored, holistic approaches for managing LAPC.

What Are the Key Drivers Behind the Expanding Research and Clinical Focus on Locally Advanced Pancreatic Cancer?

The growth in research and clinical focus on locally advanced pancreatic cancer is driven by a combination of rising incidence rates, unmet medical needs, technological innovation, and growing awareness of the disease’s unique therapeutic window. As global rates of pancreatic cancer continue to increase, partly due to aging populations and lifestyle factors such as obesity and diabetes, the burden of LAPC is becoming more pronounced. The high mortality associated with this disease stage has prompted intensified efforts to find more effective treatments that can improve both survival and quality of life. Advances in genomics and biomarker research are enabling a more nuanced understanding of tumor biology, allowing researchers to identify molecular subtypes and therapeutic targets specific to LAPC. Pharmaceutical companies and academic institutions are increasingly investing in clinical trials that explore novel drug combinations, immune checkpoint inhibitors, and radio-sensitizing agents that may overcome the tumor’s natural resistance. Funding from global cancer organizations and patient advocacy groups is supporting awareness campaigns and research grants aimed at early diagnosis and treatment innovation. The emergence of adaptive clinical trial designs is allowing for more efficient evaluation of therapies in real time, accelerating the path to new standards of care. Artificial intelligence and machine learning tools are also being applied to diagnostic imaging and treatment planning, offering data-driven insights that could optimize patient outcomes. As collaborative networks grow and treatment protocols become more refined, the global focus on LAPC is creating momentum for improved clinical pathways and potentially transformative breakthroughs in the years ahead.

SCOPE OF STUDY:

The report analyzes the Locally Advanced Pancreatic Cancer market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery); Administration Route (Oral Administration, Injectable Administration, Other Administration Routes); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • AB Science
  • Actuate Therapeutics Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Candel Therapeutics, Inc.
  • Clovis Oncology, Inc.
  • Eli Lilly and Company
  • EXACT Therapeutics
  • F. Hoffmann-La Roche Ltd.
  • FibroGen, Inc.
  • Fresenius Kabi AG
  • GlaxoSmithKline plc (GSK)
  • Ipsen Pharma
  • Merck & Co., Inc.
  • Novartis AG
  • Novocure Limited
  • Oncolytics Biotech Inc.
  • Pfizer Inc.
  • RenovoRx
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Verastem, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Locally Advanced Pancreatic Cancer - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • High Mortality and Limited Curative Options Throw the Spotlight on Intensified Research into LAPC Treatment Strategies
    • Advancements in Imaging and Early Detection Propel More Accurate Diagnosis and Staging of Locally Advanced Cases
    • Increasing Adoption of Neoadjuvant Therapies Strengthens Business Case for Multimodal Treatment in LAPC
    • Innovation in Radiation Techniques (SBRT, IMRT) Drives Targeted Local Control with Fewer Side Effects
    • Growth in Precision Oncology and Biomarker-Driven Therapies Spurs Demand for Molecular Profiling in LAPC Patients
    • Expanding Role of Immunotherapy and Checkpoint Inhibitors Generates Interest in Combination Regimens for LAPC
    • Rising Use of FOLFIRINOX and Modified Chemotherapy Protocols Enhances Progression-Free Survival Rates
    • Improved Access to Genetic Testing and Companion Diagnostics Supports Personalized Treatment Approaches
    • Development of Drug-Eluting Stents and Localized Drug Delivery Methods Opens New Avenues for Tumor Management
    • Global Increase in Pancreatic Cancer Incidence Sustains Clinical and Commercial Attention on LAPC
    • Healthcare System Investments in Cancer Centers of Excellence Boost Access to Multidisciplinary Care Models
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Locally Advanced Pancreatic Cancer Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Locally Advanced Pancreatic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Locally Advanced Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • JAPAN
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • CHINA
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • EUROPE
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Locally Advanced Pancreatic Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • FRANCE
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • GERMANY
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • INDIA
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Locally Advanced Pancreatic Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Locally Advanced Pancreatic Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • AFRICA
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제